Halozyme Therapeutics
- Market cap
- 12.57B
- P/E (TTM)i
- 32.49
- P/Bi
- 87.58
- EPSi
- 2.56
- Div yieldi
- 0.00%
- 52W posi
- 89%
Anonymous reader poll. Unscientific, not investment advice.
Halozyme Therapeutics shares were changing hands at 110.79, up 0.98% on the day. At current prices, the business is worth about 12.57B, the #1276 most valuable US-listed company we track. Valuation-wise, the P/E sits at 32.09, 55% above the five-year average of 20.75. Wall Street's 6-analyst consensus lands on Buy, with a price target averaging 103.83 (-6% from here). Against a 52-week band of 61.23-116.85, the shares are currently 89% of the way up.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 12% of the universe, above its 200-day average.
- Signal has read BUY for 2 months.
- Its last 6 Buy calls have averaged +9% over the following quarter.
- Recent price momentum is +51.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 13.4% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 31.8x | Better than 25% |
| Forward P/E | 12.4x | Better than 72% |
| Price / Sales | 7.5x | Better than 16% |
| P/E vs own 5-yr range | 92nd pctl | Better than 12% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 28.4% | Better than 90% |
| Net income CAGR (3Y) | 16.2% | Better than 69% |
| Free cash flow CAGR (3Y) | 14.9% | Better than 58% |
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 83.6% | Better than 94% |
| Operating margin | 57.5% | Better than 98% |
| Net margin | 22.7% | Better than 79% |
| Return on equity | 153.6% | Better than 97% |
| Return on invested capital | 16.2% | Better than 76% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 32.8% | Better than 94% |
| 6-month return | 70.3% | Better than 93% |
| 12-month return (ex latest month) | 64.5% | Better than 86% |
| Distance below 52-week high | 7.3% | Better than 85% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.7x | Better than 91% |
| Debt to assets | 84.8% | Better than 12% |
| Interest coverage | 26.8x | Better than 83% |
| Free cash flow / net income | 112.6% | Better than 50% |
Analyst View C
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | -4.1% | Better than 4% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 109.72
- Open
- 111.62
- Day range
- 110.16 - 114.00
- Avg price
- 111.67
- Volume
- 2.18M
- Turnover
- 243.36M
- Turnover ratei
- 1.94%
- Volume ratioi
- 0.90
- Amplitudei
- 3.50%
- 52-week rangei
- 61.23 - 116.85
Valuation
- P/Ei
- 43.28
- P/E (TTM)i
- 32.49
- P/Bi
- 87.58
- EPSi
- 2.56
- Book value / shi
- 1.27
- Net profit
- 290.55M
- Net assets
- 143.57M
Share structure
- Market cap
- 12.57B
- Float capi
- 12.43B
- Shares out
- 113.50M
- Float sharesi
- 112.19M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
5.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-34.36M net over the window
Short interest
- Shares short
- 15.15M
- % of floati
- 13.35%
- Days to coveri
- 11.59
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Halozyme Therapeutics (HALO)?
Halozyme Therapeutics last traded at 110.79. The quote on this page refreshes every few seconds while US markets are open.
What is Halozyme Therapeutics's market cap?
About 12.57B.
What is the P/E ratio of Halozyme Therapeutics?
The trailing twelve-month P/E is 32.49, above its own 5-year average of 20.75 — toward the top of its historical range (91.78% percentile). See the Valuation tab for the full history.
Does Halozyme Therapeutics pay a dividend?
Halozyme Therapeutics does not currently pay a regular dividend.
Is Halozyme Therapeutics a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 103.83, which implies 6.3% downside from the current price. This is not investment advice.
What is Halozyme Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Halozyme Therapeutics a B (Buy). Twelve-month momentum in the top 12% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 05:33:43 · For reference only, not investment advice and not tailored to your situation.